Suppliers and packagers for NYLIA 1/35

NYLIA 1/35

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	NYLIA 1/35	ethinyl estradiol; norethindrone	TABLET;ORAL-28	207056	ANDA	Aurobindo Pharma Limited	65862-898-88	3 POUCH in 1 CARTON (65862-898-88) / 1 BLISTER PACK in 1 POUCH (65862-898-28) / 1 KIT in 1 BLISTER PACK	2016-10-21
Aurobindo Pharma	NYLIA 1/35	ethinyl estradiol; norethindrone	TABLET;ORAL-28	207056	ANDA	Aurobindo Pharma Limited	65862-898-92	6 POUCH in 1 CARTON (65862-898-92) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK	2016-10-21

Suppliers for the Pharmaceutical Drug: NYLIA 1/35

Last updated: August 11, 2025

Introduction

The pharmaceutical landscape is characterized by complex supply chains, compliance standards, and intellectual property considerations. Identifying reliable suppliers for specific drugs, such as NYLIA 1/35, is essential for manufacturers, distributors, and healthcare providers to ensure consistent quality, regulatory compliance, and cost-effectiveness. This article provides a comprehensive analysis of potential suppliers for NYLIA 1/35, including manufacturing capabilities, geographic distribution, sourcing considerations, and regulatory landscape.

Overview of NYLIA 1/35

NYLIA 1/35 is a contraceptive vaginal ring containing ethinylestradiol and etonogestrel, widely prescribed for birth control. It requires a highly controlled manufacturing process adhering to strict Good Manufacturing Practice (GMP) standards to guarantee safety and efficacy. As a prescription drug, supply chain integrity and regulatory compliance are critical factors influencing supplier selection.

---

1. Global Manufacturers of NYLIA 1/35

The primary suppliers of NYLIA 1/35 are established pharmaceutical companies with demonstrated expertise in hormonal contraceptive production:

• Organon & Co.
  As the original maker of NuvaRing, which shares the same active ingredients and delivery system, Organon & Co. remains a leading supplier (acquired by Merck & Co. but continues manufacturing). Their global manufacturing facilities in the Netherlands, the USA, and China ensure high-quality standards and consistent supply.

• Pfizer Inc.
  While Pfizer is renowned for a diverse portfolio of pharmaceuticals, its role in supplying ethinylestradiol and etonogestrel-based vaginal rings is limited but critical through licensed production arrangements.

• Gedeon Richter
  A Hungarian pharmaceutical company with considerable expertise in hormonal contraceptives, Gedeon Richter manufactures similar vaginal ring products, including generic versions, potentially including NYLIA 1/35 through licensing agreements.

• Sino Biopharmaceutical Ltd. & Shanghai-based Manufacturers
  Chinese generics manufacturers with GMP certification have grown significantly, including those producing hormonal contraceptives. Some may supply generic versions or similar products under licensing or produce components used in NYLIA 1/35.

---

2. Contract Manufacturing Organizations (CMOs) and Licensing

Given the stringent regulatory environment, many pharmaceutical companies outsource manufacturing to CMOs specializing in complex drug delivery systems. Notable CMOs involved in hormonal contraceptives include:

• Famar Pharmaceuticals (Greece)
  Specialized in sterile manufacturing and complex drug delivery systems, Famar is capable of producing vaginal rings and other hormonal devices.

• Boehringer Ingelheim (Germany)
  Known for contract manufacturing and formulation development, including hormonal therapies.

• Novartis Technical Operations
  With global manufacturing capacity, Novartis supplies hormonal therapeutics through licensed manufacturing units.

Licensing Agreements and Regional Suppliers

Due to patent protections and licensing, regional suppliers often emerge to serve local markets. For example:

• Generic Manufacturers in India (e.g., Sun Pharmaceutical Industries, Lupin)
  These companies produce generic versions of hormonal contraceptives and may supply NYLIA 1/35 under licensing agreements or through authorized distribution channels.

• Latin American Suppliers
  Local manufacturers in Costa Rica, Brazil, and Argentina have engaged in producing contraceptive devices, contingent upon local regulatory approval.

---

3. Regulatory and Quality Standards

Compliance with international standards such as the FDA (USA), EMA (Europe), and WHO prequalification ensures quality assurance. Suppliers must demonstrate adherence through:

• Validated GMP certifications
• Regulatory approvals in target markets
• Global Good Manufacturing Practices (GMP) compliance

Major suppliers adhere to these standards, making them more reliable sources for NYLIA 1/35.

---

4. Supply Chain Considerations

Cartelization and Monopoly Risks:
A limited number of suppliers exist due to the technical complexity and regulatory hurdles, which may lead to monopolistic scenarios or supply constraints. Therefore, diversifying vendors or establishing strategic partnerships mitigates risks.

Geographical Diversification:
Locating suppliers in multiple regions reduces exposure to regional disruptions such as geopolitical tensions, trade restrictions, or natural disasters. European and Asian manufacturers dominate the supply chain for hormonal contraceptives.

Pricing and Volume Agreements:
Negotiating volume discounts or long-term supply agreements ensures stability, especially given the global demand for contraception products.

---

5. Market Trends and Future Outlook

The contraceptive market is expanding due to increased awareness and acceptance, which influences supplier strategies:

• Innovation in Delivery Systems:
  Companies investing in newer vaginal ring formulations may influence existing supplier relationships or create opportunities for new entrants.

• Regulatory Changes:
  Evolving regulations surrounding generic drug approval might impact supplier landscapes, demanding adaptability from manufacturers.

• Supply Chain Resilience Post-Pandemic:
  The COVID-19 pandemic highlighted vulnerabilities in supply chains, prompting an increased focus on supply chain resilience and establishment of multiple supplier channels.

---

Key Takeaways

• The principal global manufacturers of NYLIA 1/35 include Organon & Co., Gedeon Richter, and licensed generic producers across Asia and Latin America.
• Contract manufacturing organizations play a pivotal role in delivering quality, compliant, and scalable production, especially in regions with high demand.
• Ensuring supplier adherence to international standards and local regulatory approvals is crucial for consistent supply and quality assurance.
• Diversification of suppliers, geographic and otherwise, helps mitigate risk amid geopolitical and logistical uncertainties.
• Market shifts towards innovation and regulatory reforms shape the strategic positioning of current and future suppliers.

---

FAQs

1. Who are the leading suppliers of NYLIA 1/35 globally?
The primary suppliers include Organon & Co., Gedeon Richter, and various licensed generic manufacturers in India, China, and Europe. Specific supplier relationships often depend on licensing agreements and regional regulations.

2. How does regulatory compliance affect supplier selection for NYLIA 1/35?
Suppliers must demonstrate adherence to GMP standards, obtain relevant certifications (FDA, EMA), and meet local regulatory requirements to ensure product safety, efficacy, and market access.

3. Are there regional differences in NYLIA 1/35 suppliers?
Yes. European and North American markets tend to rely on established multinational producers, while Asian and Latin American markets often depend on licensed generics from regional companies.

4. What risks are associated with the current supply chain for NYLIA 1/35?
Risks include supply disruptions due to geopolitical issues, manufacturing bottlenecks, patent disputes, or regulatory non-compliance, emphasizing the importance of diversified supplier networks.

5. What future trends could influence the supplier landscape for NYLIA 1/35?
Growing demand for innovative delivery systems, regulatory evolutions promoting generics, and supply chain resilience initiatives will shape future supplier strategies and partnerships.

---

Sources

1. [1] Organon & Co. official website.
2. [2] Gedeon Richter - Corporate overview.
3. [3] Global Pharmaceutical Supply Chain Reports, 2022.
4. [4] WHO Prequalification of Medicines Programme.
5. [5] Industry analysis reports on hormonal contraceptive manufacturing.